These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions. Klein MD; Lee CR; Stouffer GA Pharmacogenomics; 2018 Aug; 19(13):1039-1046. PubMed ID: 30028231 [TBL] [Abstract][Full Text] [Related]
5. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention. Klein MD; Williams AK; Lee CR; Stouffer GA Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018 [TBL] [Abstract][Full Text] [Related]
7. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH; Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581 [TBL] [Abstract][Full Text] [Related]
8. Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy. Gross L; Trenk D; Jacobshagen C; Krieg A; Gawaz M; Massberg S; Baylacher M; Aradi D; Stimpfle F; Hromek J; Vogelgesang A; Hadamitzky M; Sibbing D; Geisler T Thromb Haemost; 2018 Sep; 118(9):1656-1667. PubMed ID: 30103241 [TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention. Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573 [TBL] [Abstract][Full Text] [Related]
10. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. AlMukdad S; Elewa H; Al-Badriyeh D J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168 [TBL] [Abstract][Full Text] [Related]
12. Is there a benefit for van den Broek WW; Ten Berg JM Pharmacogenomics; 2021 Aug; 22(12):727-730. PubMed ID: 34251288 [No Abstract] [Full Text] [Related]
13. Clinical Outcomes and Sustainability of Using Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454 [TBL] [Abstract][Full Text] [Related]
14. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis. Jiang M; You JH Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625 [TBL] [Abstract][Full Text] [Related]
15. Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis. Claassens DMF; Bergmeijer TO; Vos GJA; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Janssen PWA; Kelder JC; Mahmoodi BK; Deneer VHM; Ten Berg JM Circ Cardiovasc Interv; 2021 Apr; 14(4):e009434. PubMed ID: 33722066 [TBL] [Abstract][Full Text] [Related]
16. Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis. Zheng L; Yang C; Xiang L; Hao Z Biomarkers; 2019 Sep; 24(6):517-523. PubMed ID: 31215825 [TBL] [Abstract][Full Text] [Related]
17. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Jiang M; You JH Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome. Wang Y; Yan BP; Liew D; Lee VWY Pharmacogenomics J; 2018 Jan; 18(1):113-120. PubMed ID: 28117433 [TBL] [Abstract][Full Text] [Related]
19. CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention. Mohammad AM; Al-Allawi NAS J Cardiovasc Pharmacol; 2018 Jun; 71(6):347-351. PubMed ID: 29554005 [TBL] [Abstract][Full Text] [Related]
20. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]